Feasibility and Safety of Home Blood Count Measurement and Transfusions in Patients With Acute Myeloid Leukemia

Launched by RIGSHOSPITALET, DENMARK · Jul 2, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring whether patients with Acute Myeloid Leukemia (AML), a type of blood cancer, can safely and effectively manage some of their own care at home. Specifically, it looks at whether patients can measure their own blood counts (which show how healthy their blood cells are), give themselves blood or platelet transfusions, and monitor important signs like blood pressure, pulse, oxygen levels, and temperature before and after transfusions. The goal is to see if this approach is safe, works well, and could reduce the need for nurses to visit as often, potentially making treatment more convenient and less costly.

To take part, patients need to be adults (18 or older), newly diagnosed with AML within the past month, and scheduled to receive chemotherapy at home. They must also be able to speak Danish and be capable of learning how to do these tasks safely. Participants will receive thorough training and certification to perform the blood tests, transfusions, and vital sign monitoring themselves. If after two cycles of chemotherapy the patient’s cancer does not improve, they will stop participating. This study is currently recruiting patients and aims to find out if this new way of care can help patients manage their treatment safely and comfortably at home.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥ 18 years old
• • newly diagnosed with AML within four weeks
• • scheduled to receive home-based chemotherapy.
• Exclusion Criteria:
• • Patients who do not understand or speak Danish
• • Incapable of performing home-based CBC measurements and administration of transfusions.
• • Patients will be discontinued if they do not achieve remission after the second chemotherapy cycle.